CPA
MIRM icon

Capital Performance Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Capital Performance Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16
Closed -$624 – 1663
2024
Q3 		$624 Buy
+16
New +$638 ﹤0.01% 2146

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Performance Advisors's MIRM Position: Q4 2024 in Review

Capital Performance Advisors sold out of Mirum Pharmaceuticals (MIRM) in Q4 2024, closing a stake of 16 shares — an estimated $624 sold.

Capital Performance Advisors first reported a position in MIRM in Q3 2024 and held it in 1 quarter. The position peaked at $624 in Q3 2024. 205 funds tracked by Wall St. Rank hold MIRM as of Q4 2024.

  • Capital Performance Advisors reported no remaining Mirum Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 16 Mirum Pharmaceuticals shares in Q4 2024, an estimated $624.
  • Capital Performance Advisors first reported a position in Mirum Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Mirum Pharmaceuticals position peaked at $624 in Q3 2024.
  • 205 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.